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INVESTIGATION OF 
ERECTILE DYSFUNCTION
Diagnostic Testing for Vascular 
Factors in Erectile Dysfunction
Eric J. Meuleman, MD, PhD, and Willem L. Diemont, MD
Erectile dysfunction (ED), defined as insuffi­
cient rigidity of the penis to penetrate, is 
broadly classified into two categories: organic 
and psychologic. In reality, most of the patients 
demonstrate a combination of organic and psy­
chologic components.17 Therefore, one should 
keep in mind that the term vascular ED does 
not rule out the presence of contributing psy­
chologic factors, but merely means that vascu­
lar factors are the predominant cause of ED. 
Obstruction in the penile inflow tract, denoted 
as arterial ED, and the inability to trap blood 
within the cavernous corpora, denoted as 
veno-occlusive ED, are the two causes of the 
clinical entity known as vascular ED. In diag­
nosis of ED, a frequently asked question is 
"what is the most adequate, goal-directed eval­
uation in today's cost-conscious environ­
ment?" Because current treatments are benefi­
cial for almost all types of ED, one wonders if 
it is necessary to perform any evaluation at 
all.30/38
Several tests are available for evaluating the 
penile vascular inflow and outflow tract, rang­
ing from simple pharmacotesting to enhanced 
pharmacotesting such as in pharmacopenile 
duplex ultrasonography (PPDU), cavernosom- 
etry, selective penile angiography, and radio- 
nuclear imaging. Each method has its pros and
cons, related to validity, costs, invasiveness, 
and availability. The choice of vascular tests 
should always depend on the purpose of test­
ing: assessing erectile capacity, locating a spe­
cific vascular lesion for surgical treatment, or 
defining the vascular status in groups of pa­
tients with a specific disease.
A practical purpose for diagnostic testing 
may be assessment of erectile capacity: Are ar­
terial response and veno-occlusion, together 
resulting in erectile response, sufficient for 
nonsurgical treatment of ED, such as auto-in- 
jection therapy? Or is implantation of a penile 
prosthesis necessary? An adequate test for this 
purpose is the pharmacotest in the office, or 
eventually a trial of auto-injection therapy at 
home. One should realize, however, that an 
adequate erectile response does not rule out 
obstruction in the penile inflow tract, presum­
ing that the veno-occlusive mechanism is in­
tact.
Another purpose may be that the physician 
wishes to select patients for specific surgical 
treatments such as penile revascularization or 
veno-restrictive surgery. For this purpose, 
PPDU may be used as a first-line test to dis­
criminate between hemodynamic abnormali­
ties in the penile inflow and outflow tract. If 
abnormal, more invasive tests such as caver-
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nosometry or penile angiography may be re­
quired. Today it is recognized that the best 
candidates for revascularization are younger 
men with isolated lesions in the pudendal 
artery, the common penile artery, or both, due 
to pelvic or perineal trauma, rather than older 
men with more generalized atherosclerotic oc­
clusive disease involving the cavernous 
artery.31 The best candidates for venorestric- 
tive surgery are men with anatomic abnor­
malities such as ectopic veins exiting the cav­
ernous corpora or abnormal communications 
between the cavernosum and glans/spongio­
sum. These men may have a history of pri­
mary ED, congenital penile abnormalities, 
urethral surgery, or a blunt trauma to the erect 
penis, causing a site-specific leak.63
Furthermore, it may be important for scien­
tific and clinical reasons to define the cause of 
ED in groups of patients with a chronic dis­
ease, such as diabetes mellitus or renal fail­
ure.2,24,87 In these patients, diagnostic testing 
should focus on the other, less common causes 
of ED instead of confirming the well-known ef­
fects of the chronic illness on the erectile func­
tion.
ANATOMY
The paired internal pudendal artery arises 
from the internal iliac artery and runs outward 
and downward, leaving the pelvic cavity to en­
ter the gluteal region, where it curves around 
the ischial spine to enter the ischiorectal fossa. 
At this point, it runs in the pudendal canal (Al- 
cock's canal), on the inner surface of the inter­
nal obturator muscle. It then passes downward 
and inward, piercing the urogenital diaphragm 
to divide into its terminal branches. One of 
these branches is the common penile artery 
that divides into four branches: one to the 
proximal urethral bulb, one to the corpus spon­
giosum, one to the corpus cavernosum (cav­
ernous artery), and one to the dorsum of the 
penis (deep dorsal artery). During penile an­
giography, the identification of the dorsal 
artery and the cavernous artery is important as 
a guide to the type of anastomosis required for 
revascularization. The cavernous artery pro­
vides blood to the cavernous body through 
multiple resistance helicine arteries that open 
directly into the cavernous sinusoids. Venules 
located in the subtunical space between the pe­
riphery of the erectile tissue and the tunica 
provide venous outflow from the corpora via 
the peripheral lacunae.
For the sake of convenience, the process of 
penile erection may be divided into three dif­
ferent phases—arterial response, tumescence, 
and erectile response. Although the three 
phases act in concert, each phase has its own 
pathology and diagnostic tests (Table 1).
PATHOPHYSIOLOGY OF VASCULAR
ERECTILE DYSFUNCTION
The Phase of Arterial Response
An adequate signal to initiate arterial re­
sponse must be available; psychologic, en- 
docrinologic, and neurologic pathways must be 
intact. The arterial response is initiated by relax­
ation of the smooth muscles of the helicine ar­
teries, leading to vasodilatation and, as a conse­
quence of the gradient between systemic 
arterial blood pressure and intracavernous 
blood pressure, to a flow into the cavernous si­
nusoids. In pharmacologically induced erection, 
the highest flow rates occur within the first 
minute after injection, depending on the indi­
viduals' arterial health,43 Parameters of quality 
of arterial response are peak flow velocity and 
its acceleration time as measured by PPDU, cav­
ernous artery occlusion pressure as measured 
by cavernosometry,51/70 pooling of red blood 
cells as assessed by scintigraphic evaluation,79 
or increase of cavernous oxygen tension.29
The Phase of Tumescence
Relaxation of trabecular smooth muscle fa­
cilitates dilatation of the sinusoids. Presuming 
that arterial inflow exceeds venous outflow, ar­
terial response leads to tumescence: and in­
creasing volume and pressure of the cavernous 
corpora. Parameters for tumescence are length 
and circumference of the penis.
Phase of Erectile Response
Mediated by complete relaxation of the tra­
becular smooth muscles and subsequent in­
creasing intracavernous pressure, the subtuni­
cal venules are compressed against the tunica 
albuginea termed veno-occlusion. If the veno-oc­
clusive mechanism is intact, the arterial inflow 
leads to increase of intracavernous pressure to 
levels of mean systemic arterial blood pressure 
(80 to 100 mm Hg), with higher pressures gen­
erated by perineal muscular contractions.
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Table 1. TESTING OF CAVERNOUS HEMODYNAMICS IN DIFFERENT PHASES OF ERECTION
Predominant
Phenomenon
Test Modality 
Physical Examination
PPDU
Rigiscan
Cavernosometry
Gravity cavernosometry
Radionuclear 
scintigraphy 
Cavernous oxygen tension
Phase of Maximal 
Arterial Response
Maximal Inflow
Cavernous arterial 
occlusion pressure
Pooling of 99mTc red blood cells 
Realtime P02 evaluation
Tumescence Phase
increase of Cavernous 
Volume and Pressure
Penile length and 
circumference
Circumference
Phase of Maximal 
Erectile Response
Maximal intracavernous 
Pressure
Erection angle 
Buckling force
Resistance index 
Diastolic flow velocity
Radial rigidity 
Maintenance flow 
Pressure loss
Steady-state intracavernous 
pressure 
Xenon-133 washout
Peak flow velocity 
Acceleration time 
’ Arterial diameter
Saenz de Tejada and associates75 demonstrated 
that the tone of the trabecular smooth muscle 
regulates venous outflow resistance in the cor­
pora. When the smooth muscle is contracted, 
there is low resistance to outflow. Following 
complete smooth muscle relaxation the out­
flow resistance from the corporal bodies in­
creases by approximately 100-fold; it is con­
stant and independent of intracavernous 
pressure.75 Therefore, under physiologic condi­
tions, arterial pressure rather than arterial flow 
appears to govern penile rigidity. The hemody­
namic consequence of incomplete smooth mus­
cle relaxation is the need for higher arterial 
flows to maintain intracavernous pressures.
Parameters for evaluation of the quality of 
the veno-occlusive mechanism are diastolic 
flow velocity and its derivative resistance in­
dex as measured by PPDU, maintenance flow, 
and pressure loss as measured by cavernosom­
etry and xenon-133 washout, as measured with 
scintigraphy95 (Table 2). Clinical parameters of 
erectile response are erection angle,89 buckling 
force, and radial rigidity as measured with 
Rigiscan (Dacomed Corporation, Minneapolis, 
Minnesota).13
PHARMACOTEST
A major breakthrough in the diagnosis of 
male sexual dysfunction was accomplished 
with the discovery of pharmacologically in­
ducible erection by intracavernous injection 
(ICI) of vasoactive agents.85 Theoretically, va­
soactive substances substitute for the neuro­
transmitter to activate arterial and sinusoidal 
mechanisms. Initially, a positive erectile re­
sponse, defined as a rigid erection, has been 
presumed to signify a normal vascular status, 
and neurologic or psychologic factors were 
considered as a predominant cause for ED. If 
only partial, short-lived, or no erectile response 
resulted, vascular ED was presumed,44 In clini­
cal practice, however, the interpretation of the 
pharmacotest appeared to be more compli­
cated. To date, we know that a positive erectile 
response implies normal veno-occlusive func­
tion, but not necessarily normal arterial func­
tion. A positive erectile response merely re­
flexes an intracavernous pressure equal to or 
greater than 80 mm Hg, whereas the maximum 
erectile response as determined by the sys­
temic blood pressure could be much higher. 
Pescatori and co-workers65 demonstrated that 
in 41% of responders, the gradient between 
systemic and cavernous systolic blood pressure 
gradient is more that 24 mm Hg. Conversely, a 
negative erectile response may be due to exces­
sive adrenergic constrictor tone as a result of 
anxiety.7,50 Kim and Oh26 demonstrated that the 
level of norepinephrine in penile blood during 
the pharmacotest is higher in patients with 
psychologic ED than in healthy controls or pa­
tients with vascular ED. Moreover, in the psy­
chologic group, it appeared significantly 
higher in nonresponders than in responders. 
Up to 25% of the nonresponders may show 
predominance of psychologic factors.
There are several methods to enhance diag­
nostic accuracy of pharmacotesting: (1) using 
initial high dosages or redosing, (2) synchro-
Table 2. REFERENCE VALUES OF PARAMETERS OF PPDU RECENTLY PUBLISHED IN THE LITERATURE
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Parameter
The Literature 
(agent, dosage) Standard Used
Peak flow velocity
Acceleration time
Acceleration
Dilatation
> 20 cm/s NPT
(PGE1120 fig)28
> 22 cm/s
(papaverine, 12.5 mg)49-51 History
(papaverine, 25 mg)49 +Pharm.test*
(papaverine, 50 mg)49 +Pharm.test
(pap/phen, 15/0,5 mg)49 + Pharm.test
(PGE1,10 |xg)49 +Pharm.test
>25 cm/s +NPTt + VES*
(PGE1f 10|ig)«
> 25 cm/s Systolic occlusion
(pap/phen/PGE1f ?)70 pressure
> 35 cm/s Angiography
(papaverine, 60 mg)3
> 30 cm/s History
(pap/phen, 15/0.5 mg)82
< 122 ms History
(papaverine, 12.5 mg)51
< 110 ms Angiography
(papaverine, 60 mg)61
>400 cm/s2 Angiography
(papa/phentol, 15/0.5 mg)8a
>21% History
(papaverine, 12.5 mg)49,51
(papaverine, 25 mg)49 + Pharm.test
(papaverine, 50 mg)49 +Pharm.test
(pap/phen, 15/0,5 mg)49 +Pharm.test
(PGE^ 10 jug)49 +Pharm.test
> 70% History
*(PGE1f 10 jig + (VES)34
•positive erectile response to pharmacologic stimulation. ’
^Positive sleep-related erectile response. j
^Positive erectile response to visual erotic stimulation.
Adapted from Meuleman EJ: Investigation of erectile dysfunction. Current Opinion in Urology 3:484,1993; with permission.
nized evaluation of arterial function by PPDU, 
and (3) enhancement of erectile response by 
genital self-stimulation,11 vibratory stimula­
tion,22,71,73 visual erotic stimulation (VES),86 or 
the application of a penoscrotal tourniquet.33
The most feared complication of pharma- 
cotesting is prolonged erection. The group 
most prone to prolonged erection are younger 
patients w ith nonvascular ED and a better 
baseline erectile function.37 Therefore, the dose 
used for initial testing should be adapted to the 
historic characteristics of the patients and low­
ered with suspected neurogenic or psychologi­
cal ED.93
Three different vasoactive agents are used 
for pharmacotesting: papaverine, papaverine- 
phentolamine, and prostaglandin (PGEj). 
Other drugs such as calcitonin gene-related 
peptide,80 nitric oxide donors,68 and vasoactive 
intestinal peptide (VIP) or combination of 
drugs are currently under investigation. A 
pharmacotest, using 50 mg of papaverine, may 
lead to false-negative erectile response in 25%
of nonselected impotent men, whereas pro­
longed erection m ay occur in 5.3%.67 In a mul­
ticenter study comparing papaverine, papaver- 
ine-phentolamine, and PGE17 PGEX emerged as 
the most accurate diagnostic drug, with an 
overall erection rate of 74% and a prolonged 
erection rate of only 0.1%.67 Recently, in a re­
view of the literature, Junemann and Aiken23 
found the following rates of prolonged erec­
tions during diagnostic work-up: papaverine 
9.5%, papaverine-phentolamine 5.3%, and 
PGET 2.4%. Nonresponders bear a high proba­
bility of a vascular origin w ith a predominance 
of veno-occlusive insufficiency.23
In view of a treatment-directed instead of an 
etiology-directed approach, at our institution, a 
low-dose ICI test is combined with VES. Addi­
tionally, a postinvestigation questionnaire 
(PIQ) is used to rate erection following investi­
gation when the patient has left the office. Of 
the 90 patients studied, 11% showed adequate 
erections to ICI alone (7.5 m g to 0.25 mg pa- 
paverine-phentolamine) and 67% to ICI + VES,
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whereas 23% of the in-office nonresponders 
reported adequate erections after leaving the 
office. No prolonged erections were encount­
ered.86 A negative response is followed by 
repeated tests of up to a maximum dose of 
30 mg: 1 mg papaverine-phentolamine in an
auto-injection trial at home. We believe that 
under these circumstances, the pharmacotest 
will provide an ultimate assessment of the pa­
tients' maximal responsiveness to treatment by 
intracavernous auto-injection and may make 
more invasive diagnostic techniques redun­
dant.
PHARMACOPENILE DUPLEX 
ULTRASONOGRAPHY
The development and application of sono­
graphic equipment have grown tremendously 
since Gaskell12 introduced a Doppler device for 
evaluating penile blood pressure in 1971. Early 
Doppler systems were nondirectional, that is, 
no distinction could be made between blood 
moving away from the probe and blood mov­
ing toward the probe. Nor could a distinction 
be made between the cavernous and dorsal ar­
teries. The systems could only detect presence 
of flow and were used in measurements of pe­
nile arterial pressure.1,25 In 1980, the pulsed- 
Doppler device was introduced for evaluating 
erectile dysfunction.83 This device can detect 
the direction of blood flow and uses various 
depths of sampling. Coupling of the device to 
a spectral analyzer made it possible to obtain a 
printed Doppler velocity waveform of the ves­
sel under study. In the latest development, 
PPDU, blood flow velocity waveform analysis,
✓  « 
and ultrasonographic imaging are combined to 
assess anatomical and functional parameters of 
pharmacologically stimulated penile circula­
tion simultaneously: duplex ultrasonography.
Technique of PPDU
A duplex-scanner with color flow imaging 
possibilities is used. B-mode color images and 
Doppler spectra are obtained with a 7.5 MHz 
linear-array transducer, B-mode ultrasonogra­
phy provides visualization of cavernous arter­
ies and bodies (Fig. 1). Electronic cursors are 
used to measure diameters of cavernous arter­
ies in longitudinal projection in the proximal 
penile shaft up to an axial resolution of 0.1 mm 
(Fig. 2). By using color image as a guide to the 
localization and direction of blood flow, the 
Doppler sample volume cursor is placed in 
the cavernous artery as proximal as possible in 
the infrapubic region, and the Doppler angle 
correction cursor is adjusted to match the cor­
rect axis of flow. The resulting angle-corrected 
Doppler spectrum is displayed on the monitor, 
and acceleration time, peak flow velocity, and 
end-diastolic flow velocity are measured di­
rectly from the recorded velocity tracing. That 
information is used to calculate resistance in­
dex (RI): [(peak flow velocity) -  (diastolic flow 
velocity)!/[peak flow velocity] (Fig. 3). Knowl­
edge of these parameters provides an estimate 
of penile blood flow and is a useful indicator of 
arterial inflow capacity and venous outflow.
pubic
Figure 1. The anatomy of the infra- 
region and course of the cav­
ernous artery. The transducer is 
placed longitudinally or transversely 
across the dorsal surface at the base 
of the penis and angied interiorly to­
wards the penile crus. (From Meule- 
man, EJ: The value of combined pa­
paverine testing and duplexscanning 
In men with erectile dysfunction. Int J 
Impotence Res 2:87, 1990; with per­
mission.)
Figure 2. Longitudinal ultrasonographic image of the cavernous body through the plane of the artery. To the left is the in 
frapubic region.
Furtherm ore/ pathologic conditions sucn as 
vascular calcifications or fibrosis associate 
w ith  Peyronie 's  disease can  be located (Fig, 4). 
A dd itiona lly  PPD U  m ay be helpful in s 
penile carcinom a (Fig. 5).
Since Lue and  associates42 introduced PPDU 
as a diagnostic tool, it has become the first-line 
test to define vascular ED. Initially it was used 
to assess arterial hem odynam ic disorders, bu t 
recen tly  the use  of PPDU as a m eans of evalu­
ating veno-occlusive function is gaining accep­
tance. It has rep laced  the  m easurem ent of pe­
nile blood pressure/ whereas pudendal 
ang iography  and caver; 
served as second-line tests for patients in 
w hom  surgical repa ir  is considered,
In PPDU, the sam pling  location and  interval 
after pharm acolog ic  stim ulation are critical.27'30 
In healthy  controls, there is a m ean reduction 
of flow velocity betw een  the crural and distal 
sub coronal cavernous artery of about 20%, 
w hereas in pa tien ts  with peripheral arterial oc-
are p:re-
r> r*  I
sive disease, velocity may be reduced 
50%.27/06 With respect to location, the consensus 
in the literature is tha t velocity tracings 
be obtained in the most proximal part of the 
cavernous arteries, for example, in the crural 
part. With respect to timing, the consensus is 
that arterial response is to be determ ined in the 
phase of erection w ith highest flow rates, foi 
example, in the first m inutes 
cavernous pharmacologic stimulation.3 Follow 
mg the original s tudy  by Lue and associates,4 a 
peak flow veloci ty <  25 cm /second and a cl i -
i cavernous artery of less than 
75% have been considered to indicate arterial 
disease. To ..date, apparently  cavernous arterial 
dilatation is an unreliable param eter and m ea­
surem ent of the single Doppler param eter peak 
flow velocity is an inadequate discriminant of 
arterial disease. Current param eters are peak 
flow velocity and acceleration time. Mellinger 
and co-workers46 have added  the category of 
penile blood flow acceleration (peak flow ve-
c time
Figure 3. Doppler spectrum analysis, a-b/a ~ resistance index; ale -  acceleration; a = peak flow velocity; b = diastolic 
flow velocity; c = acceleration time.. (From Meuleman EJ, Bemelmans BLH, Van Asten WN, et al: Assessment of penile 
blood flow.. J Urol 147:51-56, 1992; with permission.)
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locity: acceleration time) to the list of duplex 
data (Fig. 3). Generally, a dampened velocity 
waveform, with long systolic acceleration time 
and a low peak flow velocity, indicates arterial 
disease (Figs, 6 through 8).
In the literature, controversies exist on ref­
erence values. In Table 1, the reference values 
published in the period of review are listed. 
The differences may be contributed to the dif­
ferent standards that were used for the selec­
tion of patients and healthy controls. More­
over, the large ranges of values may indicate 
that there is a large surplus capacity in arter­
ial supply. This means that the arterial supply 
must be severely compromised before it be­
comes a predominant cause of ED.61 It should 
be noted that arterial response has been 
shown not to depend on the type of any cur­
rently used vasoactive agent nor on external 
factors such as anxiety and stress, as long as 
supraphysiologic dosages are used.19'49 Re­
cently, Porst68 demonstrated that arterial re­
sponse after ICI of a physiologic dose of a ni­
tric oxide donor (linsidomine chlorhydrate) is 
a third less than after injection of a supra­
physiologic dose of PGEr
Veno-occlusion and erectile response are 
two closely related phenomena. In fact, veno- 
occlusive function is presumed sufficient 
when an adequate erectile response occurs. 
Because cavernous venous outflow is not 
quantifiable by PPDU, veno-occlusive func­
tion is indirectly estimated by assessing cav­
ernous venous resistance in the phase of max­
imal erectile response. Parameters are 
diastolic flow velocity32 and its derivative RI. 
In our opinion, Rl is the superior parameter 
because the most important variable associ­
ated with the process of sampling, the probe- 
vessel angle, is filtered out in the formula RI 
= (peak flow velocity -  diastolic flow veloc­
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ity) /  (peak flow velocity). Following pharma­
cologic stimulation, the value of RI adjusts to 
a level depending on intracavernous pressure. 
As soon as intracavernous pressure equals or 
exceeds systemic diastolic blood pressure, di­
astolic blood flow velocity will equal zero and 
the value for RI equals 1 (Fig. 9). As long as 
intracavernous pressure remains below sys­
temic diastolic pressure, diastolic flow will 
persist and the value for RI will remain below 
1 (Fig. 10). It has been estimated that an intra­
cavernous pressure of 80 to 100 mm Hg is 
necessary for full erection.45 As a conse­
quence, a postinjection value of 1 indicates 
full erection, whereas a postinjection value 
<  1 indicates incomplete erection. In conclu­
sion, veno-occlusive dysfunction is character­
ized by RI <  1 in the phase of maximal erec­
tile response.51
One aspect in the evaluation of the veno- 
occlusive mechanism is particularly trouble­
some: in contrast with arterial response, erec­
tile response is influenced by the type and 
dosage of the vasoactive agent and by the 
psychologic impact of the testsetting on the 
patient. This may lead to a false diagnosis of 
veno-occlusive dysfunction. This may be de­
creased by starting with a high dose of va­
soactive agent(s) or by repeated dosing.60 
Both strategies, however, bear the risk of pro­
longed erection. Furthermore, the incorpora­
tion of visual sexual stimulation, genital self­
stimulation, or vibrotactile stimulation may 
decrease psychologic inhibition and enhance 
erectile response. Our experience is that these 
additions interfere with PPDU. We found 
the patient's self-report on erectile response 
and his experience of a satisfactory sexual 
intercourse following the examination to be 
the most valid test for veno-occlusive suffi­
ciency.86
Figure 6. The hemodynamic effect of an arterial stenosis. Note the dampened velocity waveform with lonq acceleration 
time distally of the stenosis.
Figure 7. Normal velocity waveform in the crural part of the cavernous body,
CAVER NOSOMETRY
Cavernosom etry is the primary modality 
available for quantifying and mapping of 
veno-occlusive dysfunction in men with erec­
tile failure, although its ability to differentiate 
between the different types of veno-occlusive
dysfunction is limited. Because it is an invasive 
test, at our institution it is preserved for se­
at limiting venous outflow is considered, Usu­
ally, these are younger patients with a low re-
cl
Figure 8. Dampened velocity waveform in the crural part of the cavernous body.
Figure'9. Diastolic Moodfiow vàtocfty equals zero in the phase of maximal erectile response, This situation is consistent 
with a normal veno-occluslve mechanism.
normalities such as ectopic veins or abnormal
i t
spongiosum
!v
sexual s iiïm M ori, but they 
encms
intromission- They may have a
or a ^
(NPT) studies76 show  a normal frequency of
increase m
idity of erection is deficient in degree, duration, 
or both. On PPDU, they m ay have a normal ar-
in
the phase of maximal erectile response.47,48 
Veno-occlusive dysfunction may be seen as a
, This is consistent with veno-occiu-
sive dysfunction,
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multifactorial condition, with each potential 
mechanism interdependent on others. Glob­
ally, it can be classified into different patho­
physiologic subtypes: (1) Anatomic abnormali­
ties such as large and ectopic veins exiting the 
cavernous corpora. In younger men this is 
probably congenital in origin, whereas in older 
men, this is caused by alterations of the tunica 
albuginea, for example, in Peyronie's disease40 
(especially, Peyronie's plaque excision with 
heterotopic or dermal grafting can provoke 
veno-occlusive dysfunction91). Or it could be 
caused by abnormal communications between 
the cavernosum and glans/spongiosum. This 
may be congenital, posttraumatic, or due to 
priapism surgery.39 (2) Functional abnormali­
ties, typified by a limited capacitor function of 
the corpora.75 This may be due to either im­
paired relaxation of heightened cavernous 
smooth muscle contractihty10,35 Impaired relax­
ation may occur in patients with damaged 
parasympathetic dilatory nerves, such as in di­
abetes mellitus. In these cases, neurogenic ED 
presents with veno-occlusive dysfunction. Re­
cently, much attention is focused on disturbed 
intercellular communication as a possible 
mechanism of veno-occlusive dysfunction.8,59 It 
should be noted at this point that disturbed re­
laxation may be the sole effect of anxiety due 
to excessive adrenergic constrictor tone, such 
as in anxiety states.51 Therefore, psychologic 
ED such as honeymoon ED or widowers ED 
may present with veno-occlusive dysfunction. 
Other causes for impaired cavernous veno- 
ocelusion may be structural abnormalities of 
the fibro-elastic components of the trabeculae, 
as a result of aging, diabetes mellitus, vascular 
disease surgery, or trauma,9,20,74 and structural 
abnormalities of the smooth muscle cells.64
Venous resistance is regulated by the tone of 
the trabecular smooth muscle. Relaxation of 
smooth muscle allows expansion of the cor­
pora with accumulation of volume under pres­
sure, enabling the penis to act as a capacitor. 
After complete relaxation venous resistance in­
creases ± 100-fold, it is constant and indepen­
dent of intracavernous pressure.75
In cavernosometry, venous outflow resis­
tance is assessed by determining the intracav­
ernous flow rate required to sustain erection 
(intracavernous pressure > 8 0  mm Hg) in a 
state of controlled complete cavernous smooth 
muscle relaxation. Since its introduction by 
Newman and colleagues593 in 1964, several 
modifications of technique have evolved. In 
the earliest publications, a rollerpump was 
used to regulate the infusion flow rates. In 
1988, Puech Leao and associates69 introduced
an alternative technique that required less 
complicated technology and was less expen­
sive: gravity cavernosometry. Instead of using 
a rollerpump, a simple infusion set was used to 
generate a steady infusion pressure.711 Al­
though the concepts of veno-occlusive function 
and cavernosometry seem to be straightfor­
ward, method and interpretation of results 
have long been subjects of debate.84 The need 
for controlled complete smooth muscle relax­
ation has especially frustrated physicians per­
forming cavernosometry. They were con­
fronted by two critical questions: (1) What is 
the evidence that complete smooth muscle re­
laxation has occurred? (2) How can one induce 
complete muscle relaxation after initial (par­
tially failed) stimulation? Anxiety and embar­
rassment in the nonsexual situation with little 
privacy appeared to be almost incompatible 
with a state of drug-induced complete cav­
ernous relaxation. Inevitably, cavernosometry 
has overestimated the degree of structural veno- 
occlusive dysfunction.55,8^  This and the inability 
to identify individual subtypes of veno-occlu- 
sive dysfunction account for the disappointingly 
low long-term success rate of venous restrictive 
surgery (30% to 50%).66 Recently, Saenz de Te­
jada and Goldstein19* have developed a promis­
ing new method that seems to enable caver­
nosometry under conditions of known corporeal 
smooth muscle relaxation, making it more reli­
able for dinical practice.
CAVERNOSOMETRY UNDER 
CONTROLLED COMPLETE SMOOTH 
MUSCLE RELAXATION
The investigator should make every effort to 
minimize inhibiting factors by creating an at­
mosphere of privacy, for example, by limiting 
the number of personnel in the room and using 
infusion fluids at body temperature. The pa­
tient is placed supine on the fluoroscopy table. 
Three milliliters of 1% xylocaine is adminis­
tered to the subcutaneous area overlying the 
dorsal subcoronal area. Once anesthesia has 
been established, two 19-gauge needles, previ­
ously flushed with heparinized saline, are in­
troduced intracavernously. Correct placement 
is assured by flushing the needles with saline. 
The saline should pass easily, there should be 
no subcutaneous bleb forming, and no saline 
should be seen in the urethral meatus. Then, 
one needle is connected to the infusion source, 
and the other needle is connected to a pressure 
monitor. At this stage, correct placement of the 
needle can be confirmed by observation of the
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typical pressure spikes provoked by squeezing 
of the penis or straining of the patient. Blood 
pressure and pulse are monitored following 
intracavernous administration of vasoactive 
agents. Systemic side effects are characterized 
by a cardiovascular problem (syncope or hy­
potensive events associated with pallor, dizzi­
ness, sweating). These side-effects, however, 
are rather infrequent and are most likely to oc­
cur when higli-dose papaverine monosub­
stance is used. Systemic side effects with PGE2 
have not been observed.23 When symptoms de­
velop, the test is stopped and the legs of the 
patient are elevated.
The method of cavernosometry tinder con­
trolled complete cavernous smooth muscle re­
laxation is recently described by Saenz de Tejada 
and Goldstein75 following their observations in 
an animal model. The experience with the clini­
cal application has not been published in the lit­
erature yet, except for a short communication 
of Udelson and associates.81 The procedure is 
started with the injection of a combination of 30 
mg papaverine and 1 mg phentolamine (An- 
droskat, BYK Nederland BV, Zwanenburg, the 
Netherlands). In our institution, this particular 
combination is chosen because it recently has 
been approved for diagnostic and therapeutic 
purposes in the Netherlands.93 Other investiga­
tors use trimixes or even quadrimixes containing 
papaverine, phentolamine, PGET, and atropine. 
Succeeding the ICI of these vasoactive agent(s), 
steady-state intracavernous pressure is awaited. 
Then, depending on intracavernous pressure, an 
infusion pum p regulated by an intracavernous 
pressure feedback mechanism is used to mea­
sure flow necessary to maintain intracavernous 
pressures at 30, 60, 90,120, and 150 mm Hg. The 
state of complete cavernous relaxation is charac­
terized by a linear relationship between infusion 
rate and these intracavernous pressures. If a 
nonlinear relationship is demonstrated, relax­
ation is considered incomplete. Incomplete re­
laxation is induced to be complete with repeated 
administrations of vasoactive agent(s) (redos- 
ing). Most patients may require a second and 
even third dosage to attain full smooth muscle 
relaxation.15
In the literature, several parameters are used 
to measure venous resistance, such as mainte­
nance flow (MF), pressure loss (PL), and pres­
sure volume response (PVR).6,16,88
Maintenance Flow
To date, maintenance flow is considered as the 
most important parameter and involves the
recording of the flow required to maintain intra­
cavernous pressure at a level of 150 mm Hg. 
This particular level is chosen because it is 
suprasystolic and therefore isolates the mainte­
nance flow from any component of cavernous 
arterial inflow. The rate of infusion flow required 
to maintain the intracavernous pressure at 150 
mm Hg is defined as MF.88 In the era before con­
trolled complete smooth muscle relaxation, dif­
ferent reference values for MF were quoted in 
the literature. To date, we know that those differ­
ences were the result of the variability of 
smooth-muscle relaxing effect of different va­
soactive agents used among investigators, the 
different circumstances of cavernosometry, and 
the different selection criteria for healthy con­
trols.53 In patients who have a full erectile re­
sponse to intracavernous pharmacologic agents, 
it has been observed that MF is less than 3 
mL/minute.36 Therefore, 3 mL/minute can be 
considered as a cutoff value. One should keep in 
mind, however, that so far no studies have been 
performed evaluating the relationship between 
age and venocavernous resistance in a state of 
controlled smooth muscle relaxation.
If MF is considered to be abnormal and it 
can be normalized by placement of a tourni­
quet at the base of the penis, the abnormal 
drainage may be expected to be located at the 
level of the deep dorsal vein, glans penis, cor­
pus spongiosum, or superficial dorsal veins 
along the shaft of the penis. If MF is normal­
ized by the placement of perineal compression, 
then a subsequent cavemosography will demon­
strate abnormal drainage into the subsymphysic 
deep dorsal, cavernous, and crural veins.
Pressure Loss
After intracavernous pressure has been set at 
a steady-state equilibrium of 150 mm Hg, infu­
sion is stopped and pressure loss (PL) over a 
period of 30 seconds is determined. When 
veno-occlusive dysfunction is present, there is 
a low venous-outflow resistance resulting in a 
rapid fall in intracavernous pressure. A PL of 
less than 1.5 mm H g/second is considered to 
be normal.16
Pressure Volume Response
Saline infusion is started at a rate of 60 
mL/minute. If intracavernous pressure (ICP) 
does not reach 75 mm Hg after 1 minute, infu­
sion is stopped and steady state is awaited. 
Then perfusion is restarted at a rate of 120
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mL/minute. Infusion is stopped as soon as ICP 
has reached 200 mm Hg. Pressure volume re­
sponse (PVR) is then calculated by the for­
mula: PVR = ICPhKrease/volum e infused. Based 
on a study in 36 impotent males and 2 healthy 
volunteers, using the combination of 60 mg pa­
paverine and 1 mg phentolamine, Bookstein 
and associates6 selected a PVR >  1 mm H g / 
mL as criterion of normal veno-occlusion. Us­
ing 50 mg of papaverine in 96 males, we found 
a reference PVR of '1.7 mm Hg/m L. In the 
same study, comparing different parameters of 
caver nosometry/3 PL PVR and PL appeared to 
be least reliable.53 This is explained by the fact 
that both parameters are not only dependent 
on the tissue properties of the relaxed smooth 
muscle fibers and the fibro-elastic elements in 
the trabeculae and tunica albuginea but also on 
cavernous arterial pressure.
Gravity Cavernosometry
In gravity cavernosometry, the inflow needle 
is connected to a column of heparinized normal 
saline at body temperature. Free-flow delivery 
is checked by a droplet-counting chamber that 
is incorp orated in the system. In gravity caver­
nosometry, the state of complete smooth mus­
cle relaxation is demonstrated by a linear rela­
tionship between steady-state intracavernous 
pressure and different columns of heparinized 
normal saline (40, 80, 120, and 160 cm H20). 
Once complete relaxation is established, intra­
cavernous pressure at a column of 140 cm H20  
is determined. The closer intracavernous pres­
sure equals infusion pressure, the better the sta­
tus of the veno-occlusive mechanism. In a 
group of normal controls, composed of psycho­
logic impotent patients, Puech-Leao69 found 
that at a pressure of 140 cm H 20 , intracav- 
emous pressure is higher than 110 mm Hg after 
cavernous relaxation w ith 100 mg papaverine. 
In a study comparing gravity and pum p caver­
nosometry, it appeared that intracavernous 
pressure at a column of 160 cm H 20  and main­
tenance flow showed a good correlation and 
have the highest diagnostic value for veno-oc­
clusive dysfunction. To date, no results of 
gravity cavernosometry performed under con­
dition of controlled complete smooth muscle 
relaxation are available in the literature.
Cavernosography
If cavernosometry, performed in a proven 
state of complete smooth-muscle relaxation, sug­
gests that significant veno-occlusive dysfunction 
is present, the anatomic site of leakage can be 
demonstrated by intracavernous infusion of con­
trast After cavernosometry has been completed, 
a nonallergic contrast medium of low osmolality 
(Omnipaque 240 m g/m L, Nycomed, Breda, the 
Netherlands) is used to infuse the cavernous 
body. The anatomic site of draining veins is then 
real-time visualized fluoroscopically. When a 
steady-state intracavernous pressure of 90 mm 
Hg is reached, anteroposterior and right and left 
oblique films are taken. In veno-occlusive dys­
function, veins are visualized draining from the 
cavernous body during erection, in the glans, 
corpus spongiosum, the deep dorsal, cavernous, 
and crural veins. At the end of the study, the 
contrast medium is allowed to drain from the 
cavernous body and the butterfly needles re­
moved. More than one site is found in most of 
the patients, with the deep dorsal and cavernous 
veins as the most common combination.77
Cavernous Artery Occlusion Pressure
A method of functional evaluation of the cav­
ernous artery in the dynamic state is by measur­
ing its occlusion pressure, at the time of caver­
nosometry. A Doppler ultrasound transducer 
probe is placed over the left and right lateral as­
pects of the cavernous body at the base of the 
shaft to record the respective cavernous artery 
pulsating flows. The cavernous body pressure is 
elevated above the cavernous artery systolic oc­
clusion pressure by hep-arinized saline infu­
sion. The infusion is terminated as the cav­
ernous artery pulsating flow disappears. As the 
cavernous body pressure diminishes, the cav­
ernous artery pulsating flow is reestablished. 
The cavernous artery systolic occlusion pressure 
is defined as the cavernous body pressure when 
cavernous artery pulsating flow is reestablished. 
This value is compared w ith the brachial artery 
systolic occlusion pressure recorded during this 
phase. Based on observations in a normal physi­
ologic group, Padma Nathan and Goldstein62 
defined reference values by the gradient be­
tween the brachial and cavernous systolic occlu­
sion pressures: a difference of over 36 mm Hg is 
considered as abnormal cavernous artery hemo­
dynamic function.
PENILE ANGIOGRAPHY
Ginestie and Romieux14 first performed se­
lective penile angiography on impotent pa­
tients. At our institution, penile angiography is
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performed in selected cases of younger pa­
tients believed to have isolated arterial disease, 
in whom surgical repair is considered. The 
study is used to define the anatomic pattern of 
arterial occlusive disease and allows the plan­
ning of an appropriate vascular surgical ap­
proach. In the majority of patients, anatomic 
variations of the penile inflow tract can be 
demonstrated.
NUCLEAR MEDICINE IMAGING
Scintigraphic evaluation of ED was intro­
duced and developed by Shirai and Naka­
mura78 in the early seventies. This method did 
not find widespread clinical application. The 
major approaches have been either blood pool 
studies, with 99mTc-labeled red blood cells18,79 
or washout methods,94 chiefly using xenon- 
133.95 A new dynamic radioisotope technique 
is based on the simultaneous quantification of 
the change of blood volume and venous out­
flow, using a combination of blood pool and 
washout studies.54
NEW EXPERIMENTAL TESTS 
Penile Biopsy
Recently, attention has been focused on (ul- 
tra)structural investigation of cavernous tissue 
obtained by needle biopsy as a tool in the diag­
nosis of disease of the cavernous body,52,90
Penile Extensibility
Penile extensibility is correlated with age 
and erectile function4 and has been proposed 
as a method to assess the elasticity of the tu­
nica albuginea as a function of veno-occlusive 
capacity.5
Cavernous Oxygen Tension
The development of unbreakable, small-cal- 
iber oxygen-sensitive probes has advanced the 
clinical application of real-time evaluation of 
cavernous oxygen tension.29
TREATMENT OF 
PROLONGED ERECTION
The most common complication during the 
diagnostic work-up and especially during cav­
ern os ome try is pharmacologically induced
prolonged erection. Not all pharmacologically 
induced prolonged erections require a specific 
treatment because penis detumescence gener­
ally occurs within a few hours. Lue and associ­
ates41 demonstrated that in pharmacologically 
induced prolonged erection, blood gas values 
manifest inadequate blood supply to the erec­
tile tissue after 6 hours.
In case duration of erection exceeds 6 hours, 
the cavernous corpora are drained to decrease 
pressure and an adrenergic agonist is injected 
intracavernously to induce cavernous smooth 
muscle contraction, effective venous drainage, 
and restriction of arterial inflow. We use 10 /xg 
of adrenaline. The correct dose is prepared by 
adding 1 mg adrenaline to 100 mL normal 
saline, to make a solution of 10 ¡xg adrena­
line/1 mL. After a compressive bandage has 
been applied, the penis is fixed to the innerdor- 
sal site of the thigh. After 30 minutes, the ban­
dage is removed. In case an erection has re­
curred, the procedure is repeated. The blood 
pressure and pulse should be monitored dur­
ing and following adrenergic agonist adminis­
tration.
SUMMARY
To date, "several accurate tests for diagnosing 
vascular ED may be chosen. It is necessary to 
be well aware of the purpose of testing: global 
assessment of erectile capacity in preparation 
for auto-injection therapy, or detailed assess­
ment of arterial and erectile response in prepa­
ration for surgical treatment. Pharmacotesting 
may be sufficient for the majority of patients. 
Other, more invasive tests are reserved for 
preparing surgical treatment or scientific stud­
ies.
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